New hope for Tough-to-Treat blood cancer
NCT ID NCT07269639
Summary
This early-stage trial is testing a new combination of three drugs—golcadomide, poseltinib, and rituximab—for adults with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to prior treatment. The main goal is to see if this combination can shrink or eliminate the cancer and to find the safest dose. The study will enroll about 20 patients who are not eligible for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.